This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
5 Nov 2012

Emergent BioSolutions announces Phase 1b study of TRU-016

Phase 1b trials are to get underway to test the efficacy of TRU-016 in treating CLL along with rituximab.

 

Emergent BioSolution has announced the launch of Phase 1b trials of TRU-016, to be used in conjunction with rituximab for patients with untreated chronic lymphocytic leukaemia.
 

Related News